'Most Wired Survey' shows progress in tech utilization

Hospitals & Health Networks has released its 19th annual annual "Most Wired Survey," showcasing the nation’s top technological hospitals and health systems. The survey ranks facilities based on utilization of healthcare technologies including mobile health, telehealth, security system and innovation.

The survey showcases the best of the best by including categories on overall best technological utilization, most innovative, advanced security systems, small and rural hospitals and health systems, and most improved.

Findings include:

  • 60 percent of respondents have infection surveillance in electronic health record (EHR) systems.
  • 39 percent report their systems are able to deliver quality measures electronically in real time, an increase from 32 percent in 2016.
  • 82 percent have utilized tools for retrospective analytics of clinical data to identify areas of quality improvement and lowering costs.
  • Over 70 percent provide data analytic tool training to clinicians.
  • 46 percent are able to share physician notes with patients.
  • 40 percent utilize virtual visits.
  • 68 percent fill prescriptions through mobile devices.
  • 58 percent being able to restore lost data within four hours.
""
Cara Livernois, News Writer

Cara joined TriMed Media in 2016 and is currently a Senior Writer for Clinical Innovation & Technology. Originating from Detroit, Michigan, she holds a Bachelors in Health Communications from Grand Valley State University.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.